Amgen reported an earnings beat primarily due to a one-time tax benefit, while revenues declined and Aranesp sales decreased significantly. The FDA's complete response letters for Prolia may delay its approval, impacting short-term growth. Additionally, new safety concerns from the TREAT study could lead to further label changes for Aranesp, potentially pressuring sales and weighing on the stock price in the near term.

[-1]